Journal of Hospice and Palliative Care

Korean Society for Hospice and Palliative Care (한국호스피스완화의료학회)
권호 표지

The Adverse Effects of Radiotherapy and Its Management in the Hospice and Palliative Care Patients

호스피스.완화의료 환자에게 적용한 방사선 치료의 부작용과 대처법

  • Lee, Soon-Sin (Department of Family Medicine, Dong-A University College of Medicine) ;
  • Park, Young-Jin (Department of Family Medicine, Dong-A University College of Medicine) ;
  • Han, Seong-Ho (Department of Family Medicine, Dong-A University College of Medicine) ;
  • Park, Joo-Sung (Department of Family Medicine, Dong-A University College of Medicine)
  • 이순신 (동아대학교 의과대학 가정의학교실) ;
  • 박영진 (동아대학교 의과대학 가정의학교실) ;
  • 한성호 (동아대학교 의과대학 가정의학교실) ;
  • 박주성 (동아대학교 의과대학 가정의학교실)
  • Received : 2010.12.02
  • Accepted : 2011.04.18
  • Published : 2011.06.01
Download PDF
⟨ Previous Next ⟩

Abstract

Recent advances in techniques and strategies use to detect cancer in its early stages and to treat it effectively has the survival rate of cancer patients and the number of long-term cancer survivors continually increasing. Unfortunately, many cancer survivors are at risk for various late and long-term effects of cancer treatments including the radiotherapy. Long-term cancer survivors can be also seen for a hospice and palliative care because of cancer recurrence and they are at risk of delayed reactions to radiotherapy. So, the understanding and knowledge of radiation reactions is required for the proper medical diagnosis, management, and coordination of the potential reactions that may occur in these care setting. In effort to increase the survival rate in cancer patients and to decrease the adverse effects of cancer treatment, many clinical studies have been and continue to be conducted. The efforts of these studies have thus resulted in the advancement of cancer treatments. Regrettably, the overall interest in how to manage adverse effects of cancer treatment such as radiotherapy appears seemingly low in clinical practice and its advanced studies as a whole are delayed and deficient. It is imperative that the medical community show an enthusiastic interest in the aftercare of cancer patients and cancer survivors in order to create a complementary integrative approach that will eliminate radiotherapy related pain/discomfort or illness in hospice and palliative care settings.

최근 암 발생의 증가와 그에 따른 방사선 치료의 증가로 방사선 치료의 부작용은 암환자에서 치료 후 고려되어야 할 중요한 부작용 중 하나이다. 방사선 치료의 후기 부작용의 위험성이 있는 장기 암 생존자가 재발하여 호스피스 완화의료를 받게 되거나 말기암환자가 완화 목적의 방사선 치료를 받게 되는 경우 방사선 치료 부작용에 대한 이해와 지식이 이들 환자에 대한 의학적 진단 및 관리와 조정에 도움이 될 수 있을 것이다. 암환자의 생존율 향상과 암 치료 부작용의 감소를 위해 암 치료에 대한 많은 연구와 발전이 이루어지고 있지만, 임상에서 방사선 치료를 포함한 암 치료 부작용의 관리에 대한 관심은 상대적으로 적은 편이고 이에 대한 치료의 발전도 더디고 부족하다. 환자의 고통을 덜어주고 삶의 질을 유지, 향상시킬 수 있는 사후 관리를 위해 치료의 부작용과 관리에 대해 충분히 숙지할 필요가 있고, 향후 보완 통합적 접근으로 적극적인 연구와 관심이 필요할 것으로 생각된다.

Keywords

References

  1. American Cancer Society. Cancer facts and figures 2003, Atlanta, GA:American Cancer Society;2003.
  2. Ries LA, Smith MA, Gurney JG, Linet M, Tamra T, Young JL, et al, editors. Cancer incidence and survival among children and adolescents: United States SEER program 1975-1995. Bethesda, MD:National Cancer Institute;1999.
  3. Aziz NM, Rowland JH. Trends and advances in cancer survivorship research: challenge and opportunity. Semin Radiat Oncol 2003;13:248-66. https://doi.org/10.1016/S1053-4296(03)00024-9
  4. Hoskin PJ. Radiotherapy in symptom management. In: Doyle D, Hanks G, Cherny N, Calman K, eds. Oxford textbook of palliative medicine. 3rd ed. New York:Oxford University Press;2004. p. 239-55.
  5. Hall EJ, Giaccia AJ. Radiobiology for the radiologist. 6th ed. Philadelphia:Lippincott Williams & Wilkins;2006. p. 5-14.
  6. Hall EJ, Giaccia AJ. Radiobiology for the radiologist. 6th ed. Philadelphia:Lippincott Williams & Wilkins;2006. p. 47-59.
  7. Hall EJ, Giaccia AJ. Radiobiology for the radiologist. 6th ed. Philadelphia:Lippincott Williams & Wilkins;2006. p. 327-44.
  8. Olsen EA. Anagen hair loss: Radiation. In: Olsen EA, ed. Disorders of hair growth: diagnosis and treatment. New York: McGraw Hill;1994. p. 225-6.
  9. Siker ML, Donahue BR, Vogelbaum MA, Tome WA, Gilbert MR, Mehta MP. Primary intracranial neoplasms. In: Halperin EC, Perez CA, Brady LW, eds. Perez and Brady's principles and practice of radiation oncology. 5th ed. Philadelphia:Lippincott Williams & Wilkins;2008. p. 717-50.
  10. Malkinson FD, Keane JT. Radiobiology of the skin: review of some effects on epidermis and hair. J Invest Dermatol 1981;77:133-8. https://doi.org/10.1111/1523-1747.ep12479347
  11. Chopra RR, Bogart JA. Radiation therapy-related toxicity (including pneumonitis and fibrosis). Emerg Med Clin North Am 2009;27:293-310. https://doi.org/10.1016/j.emc.2009.01.010
  12. Marks JE, Baglan RJ, Prassad SC, Blank WF. Cerebral radionecrosis: incidence and risk in relation to dose, time, fractionation and volume. Int J Radiat Oncol Biol Phys 1981;7:243-52. https://doi.org/10.1016/0360-3016(81)90443-0
  13. Burger PC, Mahley MS Jr, Dudka L, Vogel FS. The morphologic effects of radiation administered therapeutically for intracranial gliomas: a postmortem study of 25 cases. Cancer 1979;44(4):1256-72. https://doi.org/10.1002/1097-0142(197910)44:4<1256::AID-CNCR2820440415>3.0.CO;2-T
  14. Lee AWM, Perez CA, Law SCK, Chua DTT, Wei WI, Chong V. Nasopharynx. In: Halperin EC, Perez CA, Brady LW, eds. Perez and Brady's principles and practice of radiation oncology. 5th ed. Philadelphia:Lippincott Williams & Wilkins;2008. p. 820-57.
  15. Henry RG, Vigneron DB, Fischbein NJ, Grant PE, Day MR, Noworolski SM, et al. Comparison of relative cerebral blood volume and proton spectroscopy in patients with treated gliomas. AJNR Am J Neuroradiol 2000;21(2):357-66.
  16. Peissner W, Kocher M, Treuer H, Gillardon F. Ionizing radiationinduced apoptosis of proliferating stem cells in the dentate gyrus of the adult rat hippocampus. Brain Res Mol Brain Res 1999;71(1):61-8. https://doi.org/10.1016/S0169-328X(99)00170-9
  17. Monje ML, Palmer T. Radiation injury and neurogenesis. Curr Opin Neurol 2003;16(2):129-34. https://doi.org/10.1097/00019052-200304000-00002
  18. Meyers CA, Weitzner MA, Valentine AD, Levin VA. Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. J Clin Oncol 1998;16(7):2522-7. https://doi.org/10.1200/JCO.1998.16.7.2522
  19. Constine LS, Woolf PD, Cann D, Mick G, McCormick K, Raubertas RF, et al. Hypothalamic-pituitary dysfunction after radiation for brain tumors. N Engl J Med 1993;328(2):87-94. Erratum in: N Engl J Med 1993;328(16):1208. https://doi.org/10.1056/NEJM199301143280203
  20. Park Y, Kim YH. Chemotherapy related oral and gastrointestinal mucositis. J Korean Med Assoc 2009;52(9):897-906. https://doi.org/10.5124/jkma.2009.52.9.897
  21. Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-Durlacher JE, et al. Mucositis study section of the multinational association of supportive care in cancer and the international society for oral oncology. Cancer 2007;109(5):820-31. https://doi.org/10.1002/cncr.22484
  22. Lee D, Jain VK. The use of recombinant human keratinocyte growth factor (palifermin) to ameliorate treatment-induced mucositis. Support Cancer Ther 2003;1:20-2. https://doi.org/10.1016/S1543-2912(13)60075-2
  23. Brizel DM, Murphy BA, Rosenthal DI, Pandya KJ, Gluck S, Brizel HE, et al. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. J Clin Oncol 2008;26:2489-96. https://doi.org/10.1200/JCO.2007.13.7349
  24. Wu HG, Song SY, Kim YS, Oh YT, Lee CG, Keum KC, et al. Therapeutic effect of recombinant human epidermal growth factor (RhEGF) on mucositis in patients undergoing radiotherapy, with or without chemotherapy, for head and neck cancer: a doubleblind placebo-controlled prospective phase 2 multi-institutional clinical trial. Cancer 2009;115:3699-708. https://doi.org/10.1002/cncr.24414
  25. Deng G, Cassileth BR. Supportive care and quality of life. In: Halperin EC, Perez CA, Brady LW, eds. Perez and Brady's principles and practice of radiation oncology. 5th ed. Philadelphia: Lippincott Williams & Wilkins;2008. p. 2011-20.
  26. Eisbruch A, Kim HM, Terrell JE, Marsh LH, Dawson LA, Ship JA. Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001;50:695-704. https://doi.org/10.1016/S0360-3016(01)01512-7
  27. Valdez IH. Radiation-induced salivary dysfunction: clinical course and significance. Spec Care Dentist 1991;11:252-5. https://doi.org/10.1111/j.1754-4505.1991.tb01490.x
  28. Ship JA, Hu K. Radiotherapy-induced salivary dysfunction. Semin Oncol 2004;31(6 Suppl 18):29-36.
  29. Brizel DM, Wasserman TH, Henke M, Strnad V, Rudat V, Monnier A, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 2000;18:3339-45. Erratum in: J Clin Oncol 2000;18:4110-1. https://doi.org/10.1200/JCO.2000.18.19.3339
  30. Anne PR, Machtay M, Rosenthal DI, Brizel DM, Morrison WH, Irwin DH, et al. A phase II trial of subcutaneous amifostine and radiation therapy in patients with head and neck cancer. Int J Radiat Oncol Biol Phys 2007;67:445-52. https://doi.org/10.1016/j.ijrobp.2006.08.044
  31. Constine LS, Milano MT, Friedman D, Morris M, Williams JP, Rubin P, et al. Late effects of cancer treatment on normal tissues. In: Halperin EC, Perez CA, Brady LW, eds. Perez and Brady's principles and practice of radiation oncology. 5th ed. Philadelphia: Lippincott Williams & Wilkins;2008. p. 320-55.
  32. Chambers MS, Garden AS, Kies MS, Martin JW. Radiationinduced xerostomia in patients with head and neck cancer: pathogenesis, impact on quality of life, and management. Head Neck 2004;26:796-807. https://doi.org/10.1002/hed.20045
  33. LeVeque FG, Montgomery M, Potter D, Zimmer MB, Rieke JW, Steiger BW, et al. A multicenter, randomized, double-blind, placebo-controlled, dose-titration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patients. J Clin Oncol 1993;11:1124-31.
  34. Wiseman LR, Faulds D. Oral pilocarpine: a review of its pharmacological properties and clinical potential in xerostomia. Drugs 1995;49:143-55. https://doi.org/10.2165/00003495-199549010-00010
  35. Johnstone PA, Peng YP, May BC, Inouye WS, Niemtzow RC. Acupuncture for pilocarpine-resistant xerostomia following radiotherapy for head and neck malignancies. Int J Radiat Oncol Biol Phys 2001;50:353-7. https://doi.org/10.1016/S0360-3016(00)01530-3
  36. Morganstein WM. Acupuncture in the treatment of xerostomia: clinical report. Gen Dent 2005;53(3):223-7.
  37. Cho JH, Chung WK, Kang W, Choi SM, Cho CK, Son CG. Manual acupuncture improved quality of life in cancer patients with radiation-induced xerostomia. J Altern Complement Med 2008;14(5):523-6. https://doi.org/10.1089/acm.2007.0793
  38. Park JH, Shin SH, Lee SW, Kim WH. Osteoradionecrosis on mandible: a case report and literature review. J Korean Oral Maxillofac Surg 2006;32:458-63.
  39. Reuther T, Schuster T, Mende U, Kubler A. Osteoradionecrosis of the jaws as a side effect of radiotherapy of head and neck tumour patients-a report of a thirty year retrospective review. Int J Oral Maxillofac Surg 2003;32:289-95. https://doi.org/10.1054/ijom.2002.0332
  40. Wong JK, Wood RE, McLean M. Conservative management of osteoradionecrosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997;84(1):16-21. https://doi.org/10.1016/S1079-2104(97)90287-0
  41. Shaha AR, Cordeiro PG, Hidalgo DA, Spiro RH, Strong EW, Zlotolow I, et al. Resection and immediate microvascular reconstruction in the management of osteoradionecrosis of the mandible. Head Neck 1997;19(5):406-11. https://doi.org/10.1002/(SICI)1097-0347(199708)19:5<406::AID-HED7>3.0.CO;2-3
  42. Tibbles PM, Edelsberg JS. Hyperbaric-oxygen therapy. N Engl J Med 1996;334(25):1642-8. https://doi.org/10.1056/NEJM199606203342506
  43. Hart GB, Mainous EG. The treatment of radiation necrosis with hyperbaric oxygen (OHP). Cancer 1976;37:2580-5. https://doi.org/10.1002/1097-0142(197606)37:6<2580::AID-CNCR2820370603>3.0.CO;2-H
  44. Blanco AI, Chao C. Management of radiation-induced head and neck injury. In: Small W, Woloschak GE, eds. Radiation toxicity: a practical guide. New York:Springer Science+Media Business, Inc.;2006. p. 23-39.
  45. Goodman M, Hilderly LJ, Purl S. Integumentary and mucous membrane alterations. In: Groenwald SL, Goodman M, Frogge MH, Yarbro CH, eds. Cancer nursing: principles and practice. 4th ed. Boston (MA): Jones and Bartlett; 1997. p. 768-822.
  46. Archambeau JO, Pezner R, Wasserman T. Pathophysiology of irradiated skin and breast. Int J Radiat Oncol Biol Phys 1995;31:1171-85. https://doi.org/10.1016/0360-3016(94)00423-I
  47. Wood G, Casey L, Trotti A. Skin changes. In: Small W, Woloschak GE, eds. Radiation toxicity: a practical guide. New York:Springer Science+Media Business, Inc.;2006. p. 170-81.
  48. Delanian S, Porcher R, Balla-Mekias S, Lefaix JL. Randomized, placebo-controlled trial of combined pentoxifylline and tocopherol for regression of superficial radiation-induced fibrosis. J Clin Oncol 2003;21(13):2545-50. https://doi.org/10.1200/JCO.2003.06.064
  49. Feldmeier JJ, Heimbach RD, Davolt DA, Court WS, Stegmann BJ, Sheffield PJ. Hyperbaric oxygen as an adjunctive treatment for delayed radiation injury of the chest wall: a retrospective review of twenty-three cases. Undersea Hyperb Med 1995;22(4):383-93.
  50. Monson JM, Stark P, Reilly JJ, Sugarbaker DJ, Strauss GM, Swanson SJ, et al. Clinical radiation pneumonitis and radiographic changes after thoracic radiation therapy for lung carcinoma. Cancer 1998;82(5):842-50. https://doi.org/10.1002/(SICI)1097-0142(19980301)82:5<842::AID-CNCR7>3.0.CO;2-L
  51. Marks LB, Yu X, Vujaskovic Z, Small W Jr, Folz R, Anscher MS. Radiation-induced lung injury. Semin Radiat Oncol 2003;13(3):333-45. https://doi.org/10.1016/S1053-4296(03)00034-1
  52. Davis SD, Yankelevitz DF, Henschke CI. Radiation effects on the lung: clinical features, pathology, and imaging findings. AJR Am J Roentgenol 1992;159(6):1157-64. https://doi.org/10.2214/ajr.159.6.1442375
  53. Kim MS. Incidence and prognostic factors of radiation pneumonitis in NSCLC treated with intensity modulated radiation therapy (IMRT). J Korean Soc Ther Radiol Oncol 2008;26(1):35-44. https://doi.org/10.3857/jkstro.2008.26.1.35
  54. Bradley J, Movsas B. Radiation pneumonitis and esophagitis in thoracic irradiation. In: Small W, Woloschak GE, eds. Radiation toxicity: a practical guide. New York:Springer Science+Media Business, Inc.;2006. p. 43-53.
  55. Marks LB, Spencer DP, Bentel GC, Ray SK, Sherouse GW, Sontag MR, et al. The utility of SPECT lung perfusion scans in minimizing and assessing the physiologic consequences of thoracic irradiation. Int J Radiat Oncol Biol Phys 1993;26:659-68. https://doi.org/10.1016/0360-3016(93)90285-4
  56. King V, Constine LS, Clark D, Schwartz RG, Muhs AG, Henzler M, et al. Symptomatic coronary artery disease after mantle irradiation for Hodgkin's disease. Int J Radiat Oncol Biol Phys 1996;36:881-9. https://doi.org/10.1016/S0360-3016(96)00295-7
  57. Heidenreich PA, Schnittger I, Strauss HW, Vagelos RH, Lee BK, Mariscal CS, et al. Screening for coronary artery disease after mediastinal irradiation for Hodgkin's disease. J Clin Oncol 2007;25:43-9. Erratum in: J Clin Oncol 2007;25(12):1635.
  58. Komaki R, Lee JS, Kaplan B, Allen P, Kelly JF, Liao Z, et al. Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: preliminary results. Semin Radiat Oncol 2002;12(1 Suppl 1):46-9. https://doi.org/10.1053/srao.2002.31363
  59. Perez CA, Kavanagh BD. Uterine Cervix. In: Halperin EC, Perez CA, Brady LW, eds. Perez and Brady's principles and practice of radiation oncology. 5th ed. Philadelphia:Lippincott Williams & Wilkins;2008. p. 1532-1609.
  60. Huh SJ. Post pelvic radiotherapy bony changes. J Korean Soc Ther Radiol Oncol 2009;27(1):1-9. https://doi.org/10.3857/jkstro.2009.27.1.1
  61. Teshima T, Hanks GE, Hanlon AL, Peter RS, Schultheiss TE. Rectal bleeding after conformal 3D treatment of prostate cancer: time to occurrence, response to treatment and duration of morbidity. Int J Radiat Oncol Biol Phys 1997;39:77-83. https://doi.org/10.1016/S0360-3016(97)00301-5
  62. Babb RR. Radiation proctitis: a review. Am J Gastroenterol 1996;91(7):1309-11.
  63. Kochhar R, Patel F, Dhar A, Sharma SC, Ayyagari S, Aggarwal R, et al. Radiation-induced proctosigmoiditis. Prospective, randomized, double-blind controlled trial of oral sulfasalazine plus rectal steroids versus rectal sucralfate. Dig Dis Sci 1991;36(1):103-7. https://doi.org/10.1007/BF01300096
  64. Corman JM, McClure D, Pritchett R, Kozlowski P, Hampson NB. Treatment of radiation induced hemorrhagic cystitis with hyperbaric oxygen. J Urol 2003;169(6):2200-2. https://doi.org/10.1097/01.ju.0000063640.41307.c9
  65. Grigsby PW, Russell A, Bruner D, Eifel P, Koh WJ, Spanos W, et al. Late injury of cancer therapy on the female reproductive tract. Int J Radiat Oncol Biol Phys 1995;31:1281-99. https://doi.org/10.1016/0360-3016(94)00426-L
  66. Cartwright-Alcarese F. Addressing sexual dysfunction following radiation therapy for a gynecologic malignancy. Oncol Nurs Forum 1995;22:1227-32. Erratum in: Oncol Nurs Forum 1995; 22:1476.
  67. Wilmoth MC, Spinelli A. Sexual implications of gynecologic cancer treatments. J Obstet Gynecol Neonatal Nurs 2000;29:413-21. https://doi.org/10.1111/j.1552-6909.2000.tb02064.x
  68. Volterrani F, Tana S, Trenti N. Topical benzydamine in the treatment of vaginal radiomucositis. Int J Tissue React 1987;9:169-71.
  69. Pitkin RM, VanVoorhis LW. Postirradiation vaginitis. An evaluation of prophylaxis with topical estrogen. Radiology 1971;99:417-21. https://doi.org/10.1148/99.2.417
  70. Robinson JW, Dufour MS, Fung TS. Erectile functioning of men treated for prostate carcinoma. Cancer 1997;79:538-44. https://doi.org/10.1002/(SICI)1097-0142(19970201)79:3<538::AID-CNCR16>3.0.CO;2-4
  71. Fransson P, Widmark A. Self-assessed sexual function after pelvic irradiation for prostate carcinoma. Comparison with an agematched control group. Cancer 1996;78:1066-78. https://doi.org/10.1002/(SICI)1097-0142(19960901)78:5<1066::AID-CNCR17>3.0.CO;2-0
  72. Incrocci L, Slob AK, Levendag PC. Sexual (dys)function after radiotherapy for prostate cancer: a review. Int J Radiat Oncol Biol Phys 2002;52:681-93. https://doi.org/10.1016/S0360-3016(01)02727-4
  73. Zelefsky MJ, McKee AB, Lee H, Leibel SA. Efficacy of oral sildenafil in patients with erectile dysfunction after radiotherapy for carcinoma of the prostate. Urology 1999;53:775-8. https://doi.org/10.1016/S0090-4295(98)00594-9
  74. Incrocci L, Slob AK, Hop WC. Tadalafil (Cialis) and erectile dysfunction after radiotherapy for prostate cancer: an open-label extension of a blinded trial. Urology 2007;70:1190-3. https://doi.org/10.1016/j.urology.2007.08.029